Literature DB >> 21181169

[Anti-TNF-α treatment for uveitis. Analysis of the current situation].

U Pleyer1, F Mackensen, S Winterhalter, N Stübiger.   

Abstract

Biologicals are selectively acting proteins that demonstrated high efficacy in the treatment of chronic disorders. In particular, biologicals blocking tumor necrosis factor α (TNF-α), an essential cytokine in chronic inflammatory diseases, have demonstrated great promise. Experimental and clinical data indicate that TNF-α plays an important role in intraocular inflammation. Neutralization of TNF-α might therefore be a promising strategy for prevention and treatment of uveitis. Here we review the principle effects, therapeutic value, and potential side effects of anti-TNF agents in uveitis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21181169     DOI: 10.1007/s00347-010-2256-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  41 in total

1.  Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis.

Authors:  H Marzo-Ortega; D McGonagle; P O'Connor; P Emery
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

Review 2.  Nod1 and Nod2 in innate immunity and human inflammatory disorders.

Authors:  L Le Bourhis; S Benko; S E Girardin
Journal:  Biochem Soc Trans       Date:  2007-12       Impact factor: 5.407

Review 3.  Infectious complications associated with monoclonal antibodies and related small molecules.

Authors:  Edsel Maurice T Salvana; Robert A Salata
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

4.  IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis.

Authors:  B E Brito; L M O'Rourke; Y Pan; J Anglin; S R Planck; J T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-10       Impact factor: 4.799

5.  Anti-TNF-alpha therapy for sight threatening uveitis.

Authors:  E W Lindstedt; G S Baarsma; R W A M Kuijpers; P M van Hagen
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

Review 6.  Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis.

Authors:  Esperanza Pato; Santiago Muñoz-Fernández; Félix Francisco; Miguel A Abad; Jesús Maese; Ana Ortiz; Loreto Carmona
Journal:  Semin Arthritis Rheum       Date:  2010-07-24       Impact factor: 5.532

Review 7.  Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.

Authors:  J Braun; X Baraliakos; J Listing; J Sieper
Journal:  Arthritis Rheum       Date:  2005-08

Review 8.  The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU).

Authors:  Andrew D Dick; John V Forrester; Janet Liversidge; Andrew P Cope
Journal:  Prog Retin Eye Res       Date:  2004-11       Impact factor: 21.198

9.  Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.

Authors:  Yukiko Yamada; Sunao Sugita; Hiroyuki Tanaka; Koju Kamoi; Tatsushi Kawaguchi; Manabu Mochizuki
Journal:  Br J Ophthalmol       Date:  2009-08-18       Impact factor: 4.638

10.  Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.

Authors:  Michael Ottiger; Michael A Thiel; Ulrich Feige; Peter Lichtlen; David M Urech
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-29       Impact factor: 4.799

View more
  6 in total

1.  [Biologics: from the "golden calf" to a "gold standard"?].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

2.  [Behcet's disease--ophthalmological and general aspects: Part 2: Therapy].

Authors:  U Pleyer; D Hazirolan; S Winterhalter; N Stübiger
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

Review 3.  [Therapy for childhood uveitis: biologics: too often--too late?].

Authors:  F Mackensen; T Lutz
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

4.  Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.

Authors:  Martin Roesel; Christoph Tappeiner; Arnd Heiligenhaus; Carsten Heinz
Journal:  Clin Ophthalmol       Date:  2011-09-13

5.  Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts.

Authors:  Alireza Mirshahi; René Hoehn; Katrin Lorenz; Christina Kramann; Holger Baatz
Journal:  J Ophthalmic Vis Res       Date:  2012-01

6.  Effect of the Toll-like receptor 4 antagonist eritoran on retinochoroidal inflammatory damage in a rat model of endotoxin-induced inflammation.

Authors:  Feyzahan Ekici; Emine Esra Karaca; Safak Korkmaz; Osman Yüksel; Özlem Gülbahar; Murat Alper; Sevim Ercan; Meral Or
Journal:  Mediators Inflamm       Date:  2014-06-17       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.